Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-038712
Filing Date
2025-03-13
Accepted
2025-03-13 16:05:20
Documents
72
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K evok-20241231.htm   iXBRL 10-K 2456772
2 EX-23.1 evok-ex23_1.htm EX-23.1 5023
3 EX-31.1 evok-ex31_1.htm EX-31.1 15156
4 EX-31.2 evok-ex31_2.htm EX-31.2 15144
5 EX-32.1 evok-ex32_1.htm EX-32.1 9955
6 EX-32.2 evok-ex32_2.htm EX-32.2 9305
7 GRAPHIC img216208575_0.jpg GRAPHIC 75290
8 GRAPHIC img216208575_1.jpg GRAPHIC 160099
  Complete submission text file 0000950170-25-038712.txt   9854981

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT evok-20241231.xsd EX-101.SCH 1458537
75 EXTRACTED XBRL INSTANCE DOCUMENT evok-20241231_htm.xml XML 1340509
Mailing Address 420 STEVENS AVENUE SUITE 230 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 230 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Filer) CIK: 0001403708 (see all company filings)

EIN.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-36075 | Film No.: 25735721
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)